Renal cell carcinoma · line 1 · Nivolumab + ipilimumab (RCC, 1L IMDC intermediate/poor)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-NIVO-IPI-RCC`

ID	`IND-RCC-METASTATIC-1L-NIVO-IPI`
Type	Indication
Status	status not declared
Diseases	`DIS-RCC`
Sources	`SRC-ESMO-RCC-2024` `SRC-NCCN-KIDNEY-2025`

Notes

CheckMate-214: nivo+ipi superior in IMDC intermediate/poor.

Used By

Algorithms

ALGO-RCC-METASTATIC-1L - ALGO-RCC-METASTATIC-1L

Red flag

RF-RCC-IMDC-INTERMEDIATE-POOR-RISK - IMDC (International Metastatic RCC Database Consortium) intermediate or poor risk score i...